1. Home
  2. HLT vs REGN Comparison

HLT vs REGN Comparison

Compare HLT & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HLT
  • REGN
  • Stock Information
  • Founded
  • HLT 1919
  • REGN 1988
  • Country
  • HLT United States
  • REGN United States
  • Employees
  • HLT N/A
  • REGN N/A
  • Industry
  • HLT Hotels/Resorts
  • REGN Biotechnology: Pharmaceutical Preparations
  • Sector
  • HLT Consumer Discretionary
  • REGN Health Care
  • Exchange
  • HLT Nasdaq
  • REGN Nasdaq
  • Market Cap
  • HLT 54.6B
  • REGN 63.4B
  • IPO Year
  • HLT 2013
  • REGN 1991
  • Fundamental
  • Price
  • HLT $243.11
  • REGN $527.78
  • Analyst Decision
  • HLT Buy
  • REGN Buy
  • Analyst Count
  • HLT 17
  • REGN 23
  • Target Price
  • HLT $241.88
  • REGN $907.39
  • AVG Volume (30 Days)
  • HLT 2.3M
  • REGN 1.2M
  • Earning Date
  • HLT 04-29-2025
  • REGN 04-29-2025
  • Dividend Yield
  • HLT 0.25%
  • REGN 0.33%
  • EPS Growth
  • HLT 37.73
  • REGN 16.49
  • EPS
  • HLT 6.35
  • REGN 39.43
  • Revenue
  • HLT $4,759,000,000.00
  • REGN $14,085,700,000.00
  • Revenue This Year
  • HLT $8.85
  • REGN $2.38
  • Revenue Next Year
  • HLT $8.99
  • REGN $7.65
  • P/E Ratio
  • HLT $38.31
  • REGN $13.39
  • Revenue Growth
  • HLT 5.20
  • REGN 7.52
  • 52 Week Low
  • HLT $194.93
  • REGN $525.99
  • 52 Week High
  • HLT $275.22
  • REGN $1,211.20
  • Technical
  • Relative Strength Index (RSI)
  • HLT 64.80
  • REGN 35.08
  • Support Level
  • HLT $235.99
  • REGN $520.50
  • Resistance Level
  • HLT $246.10
  • REGN $615.61
  • Average True Range (ATR)
  • HLT 5.78
  • REGN 22.65
  • MACD
  • HLT 3.40
  • REGN -2.54
  • Stochastic Oscillator
  • HLT 92.43
  • REGN 7.65

About HLT Hilton Worldwide Holdings Inc.

Hilton Worldwide Holdings operates more than 1.2 million rooms across its more than 20 brands serving the premium economy through luxury segments. Hampton and Hilton are the two largest brands, representing 27% and 18%, respectively, of the company's total rooms, as of Dec. 31, 2024. Recent brands launched over the last few years include Home2, Curio, Canopy, Spark, Tru, Tempo, and LivSmart, as well as a partnership with Small Luxury Hotels of the World and acquisitions of NoMad and Graduate Hotels. Managed and franchised hotels represent the vast majority of adjusted EBITDA, predominantly from the Americas.

About REGN Regeneron Pharmaceuticals Inc.

Regeneron Pharmaceuticals Inc discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).

Share on Social Networks: